C1254351||N-(1H-Pyrazol-3-yl)quinazolin-4-amines
C1171766||casein kinase 1δ
C0752519||ε
C0243077||inhibitors
C0600115||molecular modeling studies
C1254351||N-(1H-pyrazol-3-yl)quinazolin-4-amines
C0012634||disease
C0033640||protein kinases
C2247121||kinase inhibition
C1444656||indicated
C1254351||compounds
C1171766||casein kinase 1δ
C0752519||ε
C1171766||CK1δ
C0752519||ε
C0033640||kinases
C0249586||CDK5/p25
C3853562||GSK-3α
C4283740||β
C1453762||DYRK1A
C1522290||Docking
C0947630||studies
C1254351||3c
C1254351||3d
C0002520||amino acids
C0001480||ATP
C1149343||binding site
C1171766||CK1δ
C1254351||compound 3c
C1335302||pancreas ductal adenocarcinoma
C1335302||PANC-1
C0085983||cell line
C2603343||study
C1254351||N-(1H-pyrazol-3-yl)quinazolin-4-amines
C1254351||3c
C1254351||3d
C1171766||CK1δ
C0752519||ε
C0243077||inhibitor
C0524851||neurodegenerative disorders
C0006826||cancer